Degradation systems in heart failure

Journal of Molecular and Cellular Cardiology

Volumn 84, Issue , 2015, Pages 212-222

  Nishida, Kazuhiko ^a   Yamaguchi, Osamu ^b   Otsu, Kinya ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autophagy; Calpain; Heart failure; Inflammation; Ubiquitin proteasome system

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; ARE RNA BINDING PROTEIN 1; BUTYRATE RESPONSE FACTOR 1; BUTYRATE RESPONSE FACTOR 2; CALPAIN; CALPAIN 1; CALPAIN 2; CALPAIN 4; CALPASTATIN; DEOXYRIBONUCLEASE II; E1 UBIQUITIN ACTIVATING ENZYME; HU ANTIGEN; HU ANTIGEN R; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; INTERLEUKIN 6; KH TYPE SPLICING REGULATORY PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; NUCLEIC ACID;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AORTA CONSTRICTION; AUTOIMMUNITY; AUTOPHAGY; CARDIOMYOPATHY; DISEASE COURSE; DNA DEGRADATION; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FIBROSING ALVEOLITIS; HEART DILATATION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; INTRACELLULAR SIGNALING; LEFT VENTRICULAR DILATATION; MITOCHONDRION; MOLECULAR INTERACTION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; QUALITY CONTROL; REPERFUSION INJURY; REVIEW; RNA DEGRADATION; RNA STABILITY; SYSTEMIC LUPUS ERYTHEMATOSUS; THORACIC TRANSVERSE AORTIC CONSTRICTION; TRANSCRIPTION REGULATION; ANIMAL; BIOLOGICAL MODEL; HEART MUSCLE; METABOLISM; PATHOLOGY;

ANIMALS; AUTOPHAGY; HEART FAILURE; HUMANS; MODELS, BIOLOGICAL; MYOCARDIUM; NUCLEIC ACIDS; PROTEOLYSIS;

EID: 84930206951     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.05.004     Document Type: Review

References (176)

1. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128:e240-e327.
2. Wang X., Pattison J.S., Su H. Posttranslational modification and quality control. Circ Res 2013, 112:367-381.
3. Portbury A.L., Willis M.S., Patterson C. Tearin' up my heart: proteolysis in the cardiac sarcomere. J Biol Chem 2011, 286:9929-9934.
4. Yamaguchi O., Taneike M., Otsu K. Cooperation between proteolytic systems in cardiomyocyte recycling. Cardiovasc Res 2012, 96:46-52.
5. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
6. Nakayama H., Otsu K. Translation of hemodynamic stress to sterile inflammation in the heart. Trends Endocrinol Metab 2013, 24:546-553.
7. Schoenberg D.R., Maquat L.E. Regulation of cytoplasmic mRNA decay. Nat Rev Genet 2012, 13:246-259.
8. Goll D.E., Thompson V.F., Li H., Wei W., Cong J. The calpain system. Physiol Rev 2003, 83:731-801.
9. Demarchi F., Bertoli C., Copetti T., Tanida I., Brancolini C., Eskelinen E.L., et al. Calpain is required for macroautophagy in mammalian cells. J Cell Biol 2006, 175:595-605.
10. Mellgren R.L., Zhang W., Miyake K., McNeil P.L. Calpain is required for the rapid, calcium-dependent repair of wounded plasma membrane. J Biol Chem 2007, 282:2567-2575.
11. Larsen A.K., Lametsch R., Elce J., Larsen J.K., Thomsen B., Larsen M.R., et al. Genetic disruption of calpain correlates with loss of membrane blebbing and differential expression of RhoGDI-1, cofilin and tropomyosin. Biochem J 2008, 411:657-666.
12. Croall D.E., DeMartino G.N. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev 1991, 71:813-847.
13. Ono Y., Sorimachi H. Calpains: an elaborate proteolytic system. Biochim Biophys Acta 1824, 2012:224-236.
14. 2+-dependent proteinases (mu-calpain and m-calpain). J Biol Chem 1989, 264:10096-10103.
15. Arthur J.S., Elce J.S., Hegadorn C., Williams K., Greer P.A. Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol Cell Biol 2000, 20:4474-4481.
16. Takano J., Mihira N., Fujioka R., Hosoki E., Chishti A.H., Saido T.C. Vital role of the calpain-calpastatin system for placental-integrity-dependent embryonic survival. Mol Cell Biol 2011, 31:4097-4106.
17. Azam M., Andrabi S.S., Sahr K.E., Kamath L., Kuliopulos A., Chishti A.H. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol 2001, 21:2213-2220.
18. Lamb C.A., Yoshimori T., Tooze S.A. The autophagosome: origins unknown, biogenesis complex. Nat Rev Mol Cell Biol 2013, 14:759-774.
19. Mizushima N., Yoshimori T., Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol 2011, 27:107-132.
20. Mizushima N., Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011, 147:728-741.
21. Maejima Y., Chen Y., Isobe M., Gustafsson A.B., Kitsis R.N., Sadoshima J. Recent progress in research on molecular mechanisms of autophagy in the heart. Am J Physiol Heart Circ Physiol 2015, 308:H259-H268.
22. Stotland A., Gottlieb R.A. Mitochondrial quality control: easy come, easy go. Biochim Biophys Acta 2015, [in press].
23. Kobayashi S., Liang Q. Autophagy and mitophagy in diabetic cardiomyopathy. Biochim Biophys Acta 1852, 2015:252-261.
24. Moyzis A.G., Sadoshima J., Gustafsson A.B. Mending a broken heart: the role of mitophagy in cardioprotection. Am J Physiol Heart Circ Physiol 2015, 308:H183-H192.
25. Bhattacharyya S., Yu H., Mim C., Matouschek A. Regulated protein turnover: snapshots of the proteasome in action. Nat Rev Mol Cell Biol 2014, 15:122-133.
26. Pagan J., Seto T., Pagano M., Cittadini A. Role of the ubiquitin proteasome system in the heart. Circ Res 2013, 112:1046-1058.
27. Kandilis A.N., Karidis N.P., Kouraklis G., Patsouris E., Vasileiou I., Theocharis S. Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?. Expert Opin Investig Drugs 2014, 23:67-80.
28. Solomon V., Goldberg A.L. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 1996, 271:26690-26697.
29. Hinz M., Scheidereit C. The IkappaB kinase complex in NF-kappaB regulation and beyond. EMBO Rep 2014, 15:46-61.
30. Iwai K. Diverse roles of the ubiquitin system in NF-kappaB activation. Biochim Biophys Acta 1843, 2014:129-136.
31. Harhaj E.W., Dixit V.M. Regulation of NF-kappaB by deubiquitinases. Immunol Rev 2012, 246:107-124.
32. Chen Z.J., Sun L.J. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell 2009, 33:275-286.
33. Mason P.A., Cox L.S. The role of DNA exonucleases in protecting genome stability and their impact on ageing. Age (Dordr) 2012, 34:1317-1340.
34. Kavanagh D., Spitzer D., Kothari P.H., Shaikh A., Liszewski M.K., Richards A., et al. New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle 2008, 7:1718-1725.
35. Atianand M.K., Fitzgerald K.A. Molecular basis of DNA recognition in the immune system. J Immunol 2013, 190:1911-1918.
36. Napirei M., Ricken A., Eulitz D., Knoop H., Mannherz H.G. Expression pattern of the deoxyribonuclease 1 gene: lessons from the Dnase1 knockout mouse. Biochem J 2004, 380:929-937.
37. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz H.G., Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000, 25:177-181.
38. Evans C.J., Aguilera R.J. DNase II: genes, enzymes and function. Gene 2003, 322:1-15.
39. Kawane K., Ohtani M., Miwa K., Kizawa T., Kanbara Y., Yoshioka Y., et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006, 443:998-1002.
40. Yang Y.G., Lindahl T., Barnes D.E. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007, 131:873-886.
41. Stetson D.B., Ko J.S., Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
42. Brooks S.A., Blackshear P.J. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim Biophys Acta 1829, 2013:666-679.
43. Sanduja S., Blanco F.F., Dixon D.A. The roles of TTP and BRF proteins in regulated mRNA decay. Wiley Interdiscip Rev RNA 2011, 2:42-57.
44. Griseri P., Pages G. Control of pro-angiogenic cytokine mRNA half-life in cancer: the role of AU-rich elements and associated proteins. J Interferon Cytokine Res 2014, 34:242-254.
45. Mino T., Takeuchi O. Post-transcriptional regulation of cytokine mRNA controls the initiation and resolution of inflammation. Biotechnol Genet Eng Rev 2013, 29:49-60.
46. Gratacos F.M., Brewer G. The role of AUF1 in regulated mRNA decay. Wiley Interdiscip Rev RNA 2010, 1:457-473.
47. Briata P., Chen C.Y., Ramos A., Gherzi R. Functional and molecular insights into KSRP function in mRNA decay. Biochim Biophys Acta 1829, 2013:689-694.
48. Gherzi R., Chen C.Y., Ramos A., Briata P. KSRP controls pleiotropic cellular functions. Semin Cell Dev Biol 2014, 34:2-8.
49. Kotta-Loizou I., Giaginis C., Theocharis S. Clinical significance of HuR expression in human malignancy. Med Oncol 2014, 31:161.
50. Carballo E. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998, 281:1001-1005.
51. Taylor G.A., Carballo E., Lee D.M., Lai W.S., Thompson M.J., Patel D.D., et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996, 4:445-454.
52. Carballo E. Roles of tumor necrosis factor-alpha receptor subtypes in the pathogenesis of the tristetraprolin-deficiency syndrome. Blood 2001, 98:2389-2395.
53. Sandler H., Stoecklin G. Control of mRNA decay by phosphorylation of tristetraprolin. Biochem Soc Trans 2008, 36:491-496.
54. Stoecklin G., Lu M., Rattenbacher B., Moroni C. A constitutive decay element promotes tumor necrosis factor alpha mRNA degradation via an AU-rich element-independent pathway. Mol Cell Biol 2003, 23:3506-3515.
55. Moraes K.C., Wilusz C.J., Wilusz J. CUG-BP binds to RNA substrates and recruits PARN deadenylase. RNA 2006, 12:1084-1091.
56. Xiao L., Wang J.Y. RNA-binding proteins and microRNAs in gastrointestinal epithelial homeostasis and diseases. Curr Opin Pharmacol 2014, 19:46-53.
57. Uehata T., Akira S. mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1. Biochim Biophys Acta 1829, 2013:708-713.
58. Matsushita K., Takeuchi O., Standley D.M., Kumagai Y., Kawagoe T., Miyake T., et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 2009, 458:1185-1190.
59. Jones M.R., Quinton L.J., Blahna M.T., Neilson J.R., Fu S., Ivanov A.R., et al. Zcchc11-dependent uridylation of microRNA directs cytokine expression. Nat Cell Biol 2009, 11:1157-1163.
60. Pautz A., Linker K., Hubrich T., Korhonen R., Altenhofer S., Kleinert H. The polypyrimidine tract-binding protein (PTB) is involved in the post-transcriptional regulation of human inducible nitric oxide synthase expression. J Biol Chem 2006, 281:32294-32302.
61. Carpenter S., Ricci E.P., Mercier B.C., Moore M.J., Fitzgerald K.A. Post-transcriptional regulation of gene expression in innate immunity. Nat Rev Immunol 2014, 14:361-376.
62. Zhang J., Sun X., Qian Y., LaDuca J.P., Maquat L.E. At least one intron is required for the nonsense-mediated decay of triosephosphate isomerase mRNA: a possible link between nuclear splicing and cytoplasmic translation. Mol Cell Biol 1998, 18:5272-5283.
63. Clubb F.J., Bishop S.P. Formation of binucleated myocardial cells in the neonatal rat. An index for growth hypertrophy. Lab Investig 1984, 50:571-577.
64. Bergmann O., Bhardwaj R.D., Bernard S., Zdunek S., Barnabe-Heider F., Walsh S., et al. Evidence for cardiomyocyte renewal in humans. Science 2009, 324:98-102.
65. Huang J., Forsberg N.E. Role of calpain in skeletal-muscle protein degradation. Proc Natl Acad Sci U S A 1998, 95:12100-12105.
66. Whipple G., Koohmaraie M. Degradation of myofibrillar proteins by extractable lysosomal enzymes and m-calpain, and the effects of zinc chloride. J Anim Sci 1991, 69:4449-4460.
67. Ho C.Y., Stromer M.H., Robson R.M. Identification of the 30kDa polypeptide in post mortem skeletal muscle as a degradation product of troponin-T. Biochimie 1994, 76:369-375.
68. Barta J., Toth A., Edes I., Vaszily M., Papp J.G., Varro A., et al. Calpain-1-sensitive myofibrillar proteins of the human myocardium. Mol Cell Biochem 2005, 278:1-8.
69. Steinberg S.F. Oxidative stress and sarcomeric proteins. Circ Res 2013, 112:393-405.
70. Matsumura Y., Saeki E., Otsu K., Morita T., Takeda H., Kuzuya T., et al. Intracellular calcium level required for calpain activation in a single myocardial cell. J Mol Cell Cardiol 2001, 33:1133-1142.
71. Galvez A.S., Diwan A., Odley A.M., Hahn H.S., Osinska H., Melendez J.G., et al. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res 2007, 100:1071-1078.
72. Yoshida K., Yamasaki Y., Kawashima S. Calpain activity alters in rat myocardial subfractions after ischemia or reperfusion. Biochim Biophys Acta 1993, 1182:215-220.
73. Inserte J., Hernando V., Garcia-Dorado D. Contribution of calpains to myocardial ischaemia/reperfusion injury. Cardiovasc Res 2012, 96:23-31.
74. Hikoso S., Ikeda Y., Yamaguchi O., Takeda T., Higuchi Y., Hirotani S., et al. Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer. J Am Coll Cardiol 2007, 50:453-462.
75. Takahashi M., Tanonaka K., Yoshida H., Oikawa R., Koshimizu M., Daicho T., et al. Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. Cardiovasc Res 2005, 65:356-365.
76. Letavernier E., Perez J., Bellocq A., Mesnard L., de Castro Keller A., Haymann J.P., et al. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 2008, 102:720-728.
77. Li X., Li Y., Shan L., Shen E., Chen R., Peng T. Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia. Cardiovasc Res 2009, 83:72-79.
78. Ma J., Wei M., Wang Q., Li J., Wang H., Liu W., et al. Deficiency of Capn4 gene inhibits nuclear factor-kappaB (NF-kappaB) protein signaling/inflammation and reduces remodeling after myocardial infarction. J Biol Chem 2012, 287:27480-27489.
79. Taneike M., Mizote I., Morita T., Watanabe T., Hikoso S., Yamaguchi O., et al. Calpain protects the heart from hemodynamic stress. J Biol Chem 2011, 286:32170-32177.
80. McNeil P. Membrane repair redux: redox of MG53. Nat Cell Biol 2009, 11:7-9.
81. Cai C., Masumiya H., Weisleder N., Matsuda N., Nishi M., Hwang M., et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 2009, 11:56-64.
82. Lek A., Evesson F.J., Lemckert F.A., Redpath G.M., Lueders A.K., Turnbull L., et al. Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-dependent muscle membrane repair. J Neurosci 2013, 33:5085-5094.
83. McNeil A.K., Rescher U., Gerke V., McNeil P.L. Requirement for annexin A1 in plasma membrane repair. J Biol Chem 2006, 281:35202-35207.
84. Steinhardt R.A., Bi G., Alderton J.M. Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science 1994, 263:390-393.
85. Nakai A., Yamaguchi O., Takeda T., Higuchi Y., Hikoso S., Taniike M., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007, 13:619-624.
86. Nishida Y., Arakawa S., Fujitani K., Yamaguchi H., Mizuta T., Kanaseki T., et al. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 2009, 461:654-658.
87. Honda S., Arakawa S., Nishida Y., Yamaguchi H., Ishii E., Shimizu S. Ulk1-mediated Atg5-independent macroautophagy mediates elimination of mitochondria from embryonic reticulocytes. Nat Commun 2014, 5:4004.
88. Taneike M., Yamaguchi O., Nakai A., Hikoso S., Takeda T., Mizote I., et al. Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy 2010, 6:600-606.
89. Osterholt M., Nguyen T.D., Schwarzer M., Doenst T. Alterations in mitochondrial function in cardiac hypertrophy and heart failure. Heart Fail Rev 2013, 18:645-656.
90. Oyabu J., Yamaguchi O., Hikoso S., Takeda T., Oka T., Murakawa T., et al. Autophagy-mediated degradation is necessary for regression of cardiac hypertrophy during ventricular unloading. Biochem Biophys Res Commun 2013, 441:787-792.
91. Tarazi R.C., Fouad F.M. Reversal of cardiac hypertrophy by medical treatment. Annu Rev Med 1985, 36:407-414.
92. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507-1513.
93. Hariharan N., Ikeda Y., Hong C., Alcendor R.R., Usui S., Gao S., et al. Autophagy plays an essential role in mediating regression of hypertrophy during unloading of the heart. PLoS One 2013, 8:e51632.
94. Cao D.J., Jiang N., Blagg A., Johnstone J.L., Gondalia R., Oh M., et al. Mechanical unloading activates FoxO3 to trigger Bnip3-dependent cardiomyocyte atrophy. J Am Heart Assoc 2013, 2:e000016.
95. Nishida K., Kyoi S., Yamaguchi O., Sadoshima J., Otsu K. The role of autophagy in the heart. Cell Death Differ 2009, 16:31-38.
96. Danon M.J., Oh S.J., DiMauro S., Manaligod J.R., Eastwood A., Naidu S., et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981, 31:51-57.
97. Cheng Z., Fang Q. Danon disease: focusing on heart. J Hum Genet 2012, 57:407-410.
98. Tanaka Y., Guhde G., Suter A., Eskelinen E.L., Hartmann D., Lullmann-Rauch R., et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000, 406:902-906.
99. Nishino I., Fu J., Tanji K., Yamada T., Shimojo S., Koori T., et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000, 406:906-910.
100. Vicart P., Caron A., Guicheney P., Li Z., Prevost M.C., Faure A., et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 1998, 20:92-95.
101. Tannous P., Zhu H., Johnstone J.L., Shelton J.M., Rajasekaran N.S., Benjamin I.J., et al. Autophagy is an adaptive response in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A 2008, 105:9745-9750.
102. Bhuiyan M.S., Pattison J.S., Osinska H., James J., Gulick J., McLendon P.M., et al. Enhanced autophagy ameliorates cardiac proteinopathy. J Clin Invest 2013, 123:5284-5297.
103. Zhu H., Tannous P., Johnstone J.L., Kong Y., Shelton J.M., Richardson J.A., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007, 117:1782-1793.
104. Rothermel B.A., Hill J.A. Autophagy in load-induced heart disease. Circ Res 2008, 103:1363-1369.
105. Day S.M. The ubiquitin proteasome system in human cardiomyopathies and heart failure. Am J Physiol Heart Circ Physiol 2013, 304:H1283-H1293.
106. Li J., Horak K.M., Su H., Sanbe A., Robbins J., Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest 2011, 121:3689-3700.
107. Li J., Powell S.R., Wang X. Enhancement of proteasome function by PA28alpha overexpression protects against oxidative stress. FASEB J 2011, 25:883-893.
108. Bulteau A.L., Lundberg K.C., Humphries K.M., Sadek H.A., Szweda P.A., Friguet B., et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 2001, 276:30057-30063.
109. Divald A., Powell S.R. Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic Biol Med 2006, 40:156-164.
110. Tian Z., Zheng H., Li J., Li Y., Su H., Wang X. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res 2012, 111:532-542.
111. Divald A., Kivity S., Wang P., Hochhauser E., Roberts B., Teichberg S., et al. Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ Res 2010, 106:1829-1838.
112. Predmore J.M., Wang P., Davis F., Bartolone S., Westfall M.V., Dyke D.B., et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 2010, 121:997-1004.
113. Birks E.J., Latif N., Enesa K., Folkvang T., Luong le A., Sarathchandra P., et al. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 2008, 79:472-480.
114. Kassiotis C., Ballal K., Wellnitz K., Vela D., Gong M., Salazar R., et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation 2009, 120:S191-S197.
115. Wohlschlaeger J., Sixt S.U., Stoeppler T., Schmitz K.J., Levkau B., Tsagakis K., et al. Ventricular unloading is associated with increased 20s proteasome protein expression in the myocardium. J Heart Lung Transplant 2010, 29:125-132.
116. Calise J., Powell S.R. The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol 2013, 304:H337-H349.
117. Powell S.R., Wang P., Katzeff H., Shringarpure R., Teoh C., Khaliulin I., et al. Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal 2005, 7:538-546.
118. Meiners S., Ludwig A., Lorenz M., Dreger H., Baumann G., Stangl V., et al. Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med 2006, 40:2232-2241.
119. Meiners S., Ludwig A., Stangl V., Stangl K. Proteasome inhibitors: poisons and remedies. Med Res Rev 2008, 28:309-327.
120. Elliott P.J., Zollner T.M., Boehncke W.H. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med (Berl) 2003, 81:235-245.
121. Pye J., Ardeshirpour F., McCain A., Bellinger D.A., Merricks E., Adams J., et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 2003, 284:H919-H926.
122. Stangl K., Gunther C., Frank T., Lorenz M., Meiners S., Ropke T., et al. Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem Biophys Res Commun 2002, 291:542-549.
123. Van der Heiden K., Cuhlmann S., Luong le A., Zakkar M., Evans P.C. Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) 2010, 118:593-605.
124. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.
125. Sag C.M., Santos C.X., Shah A.M. Redox regulation of cardiac hypertrophy. J Mol Cell Cardiol 2014, 73:103-111.
126. Ushio-Fukai M. Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 2009, 11:1289-1299.
127. Amin J.K., Xiao L., Pimental D.R., Pagano P.J., Singh K., Sawyer D.B., et al. Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001, 33:131-139.
128. Pimentel D.R., Amin J.K., Xiao L., Miller T., Viereck J., Oliver-Krasinski J., et al. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 2001, 89:453-460.
129. Xiao L., Pimentel D.R., Wang J., Singh K., Colucci W.S., Sawyer D.B. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 2002, 282:C926-C934.
130. Aikawa R., Nagai T., Tanaka M., Zou Y., Ishihara T., Takano H., et al. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun 2001, 289:901-907.
131. Tanaka K., Honda M., Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 2001, 37:676-685.
132. Nakamura K., Fushimi K., Kouchi H., Mihara K., Miyazaki M., Ohe T., et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998, 98:794-799.
133. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002, 105:509-515.
134. Higuchi Y., Otsu K., Nishida K., Hirotani S., Nakayama H., Yamaguchi O., et al. Involvement of reactive oxygen species-mediated NF-kappaB activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 2002, 34:233-240.
135. Hirotani S., Higuchi Y., Nishida K., Nakayama H., Yamaguchi O., Hikoso S., et al. Ca(2+)-sensitive tyrosine kinase Pyk2/CAK beta-dependent signaling is essential for G-protein-coupled receptor agonist-induced hypertrophy. J Mol Cell Cardiol 2004, 36:799-807.
136. Higuchi Y., Otsu K., Nishida K., Hirotani S., Nakayama H., Yamaguchi O., et al. The small GTP-binding protein Rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis signal-regulating kinase 1 and nuclear factor-kappaB. J Biol Chem 2003, 278:20770-20777.
137. Anderson M.E., Brown J.H., Bers D.M. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 2011, 51:468-473.
138. Kashiwase K., Higuchi Y., Hirotani S., Yamaguchi O., Hikoso S., Takeda T., et al. CaMKII activates ASK1 and NF-kappaB to induce cardiomyocyte hypertrophy. Biochem Biophys Res Commun 2005, 327:136-142.
139. Freund C., Schmidt-Ullrich R., Baurand A., Dunger S., Schneider W., Loser P., et al. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005, 111:2319-2325.
140. Kawano S., Kubota T., Monden Y., Tsutsumi T., Inoue T., Kawamura N., et al. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol 2006, 291:H1337-H1344.
141. Kawamura N., Kubota T., Kawano S., Monden Y., Feldman A.M., Tsutsui H., et al. Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovasc Res 2005, 66:520-529.
142. Hamid T., Guo S.Z., Kingery J.R., Xiang X., Dawn B., Prabhu S.D. Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res 2011, 89:129-138.
143. Gordon J.W., Shaw J.A., Kirshenbaum L.A. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 2011, 108:1122-1132.
144. Misra A., Haudek S.B., Knuefermann P., Vallejo J.G., Chen Z.J., Michael L.H., et al. Nuclear factor-kappaB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation 2003, 108:3075-3078.
145. Kratsios P., Huth M., Temmerman L., Salimova E., Al Banchaabouchi M., Sgoifo A., et al. Antioxidant amelioration of dilated cardiomyopathy caused by conditional deletion of NEMO/IKKgamma in cardiomyocytes. Circ Res 2010, 106:133-144.
146. Maekawa N., Wada H., Kanda T., Niwa T., Yamada Y., Saito K., et al. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol 2002, 39:1229-1235.
147. Timmers L., van Keulen J.K., Hoefer I.E., Meijs M.F., van Middelaar B., den Ouden K., et al. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res 2009, 104:699-706.
148. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
149. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
150. Ding W.X., Ni H.M., Gao W., Yoshimori T., Stolz D.B., Ron D., et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007, 171:513-524.
151. Komatsu M., Waguri S., Koike M., Sou Y.S., Ueno T., Hara T., et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007, 131:1149-1163.
152. Korolchuk V.I., Mansilla A., Menzies F.M., Rubinsztein D.C. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009, 33:517-527.
153. Xia H.G., Zhang L., Chen G., Zhang T., Liu J., Jin M., et al. Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy 2010, 6:61-66.
154. Yousefi S., Perozzo R., Schmid I., Ziemiecki A., Schaffner T., Scapozza L., et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 2006, 8:1124-1132.
155. Kuribara J., Tada H., Kawai Y., Kawaguchi R., Hoshizaki H., Arakawa K., et al. Levels of serum deoxyribonuclease I activity on admission in patients with acute myocardial infarction can be useful in predicting left ventricular enlargement due to remodeling. J Cardiol 2009, 53:196-203.
156. Morikawa N., Kawai Y., Arakawa K., Kumamoto T., Miyamori I., Akao H., et al. Serum deoxyribonuclease I activity can be used as a novel marker of transient myocardial ischaemia: results in vasospastic angina pectoris induced by provocation test. Eur Heart J 2007, 28:2992-2997.
157. Yasuda T., Iida R., Kawai Y., Nakajima T., Kominato Y., Fujihara J., et al. Serum deoxyribonuclease I can be used as a useful marker for diagnosis of death due to ischemic heart disease. Leg Med (Tokyo) 2009, 11(Suppl. 1):S213-S215.
158. Li G.H., Shi Y., Chen Y., Sun M., Sader S., Maekawa Y., et al. Gelsolin regulates cardiac remodeling after myocardial infarction through DNase I-mediated apoptosis. Circ Res 2009, 104:896-904.
159. Savchenko A.S., Borissoff J.I., Martinod K., De Meyer S.F., Gallant M., Erpenbeck L., et al. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood 2014, 123:141-148.
160. Morita M., Stamp G., Robins P., Dulic A., Rosewell I., Hrivnak G., et al. Gene-targeted mice lacking the Trex1 (DNase III) 3'→5' DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004, 24:6719-6727.
161. Gray M.W. Mitochondrial evolution. Science 1999, 283:1476-1481.
162. Pollack Y., Kasir J., Shemer R., Metzger S., Szyf M. Methylation pattern of mouse mitochondrial DNA. Nucleic Acids Res 1984, 12:4811-4824.
163. Cardon L.R., Burge C., Clayton D.A., Karlin S. Pervasive CpG suppression in animal mitochondrial genomes. Proc Natl Acad Sci U S A 1994, 91:3799-3803.
164. Yakes F.M., Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A 1997, 94:514-519.
165. Oka T., Hikoso S., Yamaguchi O., Taneike M., Takeda T., Tamai T., et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012, 485:251-255.
166. Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.
167. Bliksoen M., Mariero L.H., Ohm I.K., Haugen F., Yndestad A., Solheim S., et al. Increased circulating mitochondrial DNA after myocardial infarction. Int J Cardiol 2012, 158:132-134.
168. Nakahira K., Haspel J.A., Rathinam V.A., Lee S.J., Dolinay T., Lam H.C., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011, 12:222-230.
169. Shimada K., Crother T.R., Karlin J., Dagvadorj J., Chiba N., Chen S., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36:401-414.
170. Hikoso S., Yamaguchi O., Higuchi Y., Hirotani S., Takeda T., Kashiwase K., et al. Pressure overload induces cardiac dysfunction and dilation in signal transducer and activator of transcription 6-deficient mice. Circulation 2004, 110:2631-2637.
171. Condorelli G., Latronico M.V., Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 2014, 63:2177-2187.
172. Kumarswamy R., Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013, 113:676-689.
173. Geiger S.K., Bär H., Ehlermann P., Wälde S., Rutschow D., Zeller R., et al. Incomplete nonsense-mediated decay of mutant lamin A/C mRNA provokes dilated cardiomyopathy and ventricular tachycardia. J Mol Med 2008, 86:281-289.
174. Okamoto K., Kondo-Okamoto N., Ohsumi Y. Mitochondria-anchored receptor Atg32 mediates degradation of mitochondria via selective autophagy. Dev Cell 2009, 17:87-97.
175. Seta Y., Shan K., Bozkurt B., Oral H., Mann D.L. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996, 2:243-249.
176. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.